Download PDF

1. Company Snapshot

1.a. Company Description

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United States, Europe, and internationally.The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform.Its OA pain management product family consists of Monovisc, Orthovisc, Cingal, and Hyvisc that are indicated to provide pain relief from osteoarthritis conditions; and joint preservation and restoration product family comprise a portfolio of approximately 150 bone preserving joint technology products, a line of sports medicine soft tissue repair solutions, and orthopedic regenerative solutions products.


The company's non-orthopedic product family include HA-based products for non-orthopedic applications, including adhesion barrier products, advanced wound care products, ophthalmic products, and ear, nose, and throat products.Anika Therapeutics, Inc.was founded in 1983 and is headquartered in Bedford, Massachusetts.

Show Full description

1.b. Last Insights on ANIK

Recent news surrounding Anika Therapeutics, Inc. suggests a negative impact on its stock performance. The company's decision to divest Parcus Medical, announced on March 7, 2025, may indicate a shift in focus away from certain business segments. This move may have sparked investor concerns about the company's future prospects. Additionally, the lack of recent earnings release and investor conference calls, such as the one scheduled for March 12, 2025, may have contributed to the uncertainty.

1.c. Company Highlights

2. Anika's Financial Performance

Anika Therapeutics reported revenue of $112.8 million for the full year 2025, a decline of 6% compared to the prior year. However, the company's commercial channel revenue grew 15% to $48.4 million, driven by strong performance in international OA pain management and continued adoption of Integrity. The GAAP gross margin for the full year was 57%, and adjusted EBITDA was $5.3 million or approximately 5% of revenue. The company's EPS was $0.31, beating analyst estimates of $0.02.

Publication Date: Mar -09

📋 Highlights
  • Commercial Channel Growth:: Revenue increased 15% to $48.4M in 2025, driven by 12% growth in international OA pain management and Integrity procedures surpassing $6M.
  • Operational Margin Improvement:: GAAP gross margin rose to 57% for the year and 63% in Q4, up from 56% in the prior year, reflecting cost efficiencies.
  • Innovation Pipeline Progress:: Hyalofast submitted final PMA to FDA, while Cingal reached 1 million injections across 40+ international markets.
  • Revenue Decline Offset by Strategic Shifts:: Total revenue fell 6% to $112.8M, but commercial channel grew 15% amid 17% OEM decline, signaling business mix changes.
  • 2026 Guidance Optimism:: Anticipates 1–9% total revenue growth ($114M–$122.5M), with commercial channel projected to rise 10–20% to $53M–$58M.

Revenue Growth Drivers

The commercial channel revenue growth was led by a 12% increase in international OA pain revenue and a significant increase in Integrity procedures and revenue, which more than doubled to approximately $6 million. The company's innovation pipeline also made progress, with Hyalofast submitting the third module of its PMA to the FDA, and Cingal surpassing 1 million injections across more than 40 international markets.

Operational Execution

Anika's operational execution improved, with expanded gross margins, positive operating income for the fourth quarter, and meaningful free cash flow. The company's gross GAAP gross margin increased to 63% from 56% in the prior year. Total adjusted EBITDA from continuing operations was $4.5 million for the fourth quarter.

Outlook and Guidance

Anika is maintaining its previously communicated revenue guidance ranges by channel and introducing a total company revenue outlook for 2026. The company expects revenue between $114 million and $122.5 million, representing 1% to 9% year-over-year growth, driven by momentum in the commercial channel and market dynamics in the OEM business. Analysts estimate next year's revenue growth at 7.4%.

Valuation Metrics

Anika's valuation metrics indicate a mixed picture. The company's P/E Ratio is -18.52, indicating that it is not profitable on a trailing twelve-month basis. However, the P/B Ratio is 1.4, and the P/S Ratio is 1.8, suggesting that the stock may be undervalued. The EV/EBITDA ratio is -41.66, and the Free Cash Flow Yield is 2.14%. According to Anika's President, Steve Griffin, "we are confident in our ability to drive revenue growth, improve profitability, and create value for our shareholders."

Future Plans

The company plans to invest in manufacturing capability, U.S. sales channel, and executing on strategic priorities, with no immediate plans for tuck-in M&A. Anika has completed toxicity studies for Cingal and is progressing with a bioequivalent study, with a targeted enrollment of just under 60 patients.

3. NewsRoom

Card image cap

Anika to Issue First Quarter 2026 Financial Results on Wednesday, April 29, 2026

Apr -15

Source: globenewswire.com

Card image cap

Is Anika Therapeutics Inc (ANIK) a Bargain After 3.1% Drop? GF Value Says Undervalued

Apr -10

Source: gurufocus.com

Card image cap

Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr -03

Source: globenewswire.com

Card image cap

Top 2 Health Care Stocks That May Crash This Quarter

Mar -04

Source: benzinga.com

Card image cap

Anika Therapeutics, Inc. (ANIK) Q4 2025 Earnings Call Transcript

Feb -26

Source: seekingalpha.com

Card image cap

Anika Therapeutics (ANIK) Q4 Earnings and Revenues Beat Estimates

Feb -26

Source: zacks.com

Card image cap

Anika Reports Fourth Quarter and Full Year 2025 Financial Results

Feb -26

Source: globenewswire.com

Card image cap

Anika Therapeutics (NASDAQ:ANIK) Stock Passes Above 200 Day Moving Average – Here’s What Happened

Feb -19

Source: defenseworld.net

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (6.80%)

6. Segments

Ostoarthritis Pain Management

Expected Growth: 6.5%

Anika Therapeutics' Osteoarthritis Pain Management segment growth of 6.5% is driven by increasing prevalence of osteoarthritis, growing demand for minimally invasive treatments, and expanding adoption of hyaluronic acid-based therapies. Additionally, rising healthcare expenditure, aging population, and increasing awareness of alternative pain management options contribute to the segment's growth.

Joint Preservation and Restoration

Expected Growth: 7.5%

Anika Therapeutics' Joint Preservation and Restoration segment growth of 7.5% is driven by increasing demand for minimally invasive orthopedic procedures, expanding adoption of hyaluronic acid-based treatments, and growing awareness of early intervention for joint pain. Additionally, strategic partnerships, geographic expansion, and innovative product launches contribute to the segment's growth momentum.

Non-Orthopedic

Expected Growth: 6.0%

Anika Therapeutics' Non-Orthopedic segment growth of 6.0% is driven by increasing adoption of its hyaluronic acid-based products in the aesthetic and ophthalmic markets, coupled with expanding distribution channels and strategic partnerships. Additionally, growing demand for minimally invasive treatments and rising healthcare expenditure also contribute to this growth.

7. Detailed Products

HydraFill

A family of osteochondral allografts used for joint preservation and restoration

HydraGel

A family of hyaluronic acid-based products used for viscosupplementation and tissue augmentation

Cingal

A viscosupplement used to treat osteoarthritis

Monovisc

A single-injection viscosupplement used to treat osteoarthritis

Orthovisc

A multi-injection viscosupplement used to treat osteoarthritis

8. Anika Therapeutics, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Anika Therapeutics, Inc. has a moderate threat of substitutes due to the presence of alternative treatments and products in the market.

Bargaining Power Of Customers

Anika Therapeutics, Inc. has a low bargaining power of customers due to the specialized nature of its products and limited customer base.

Bargaining Power Of Suppliers

Anika Therapeutics, Inc. has a moderate bargaining power of suppliers due to the presence of multiple suppliers and the company's moderate dependence on them.

Threat Of New Entrants

Anika Therapeutics, Inc. has a high threat of new entrants due to the growing demand for orthobiologics and the increasing number of companies entering the market.

Intensity Of Rivalry

Anika Therapeutics, Inc. operates in a highly competitive market with several established players, leading to a high intensity of rivalry.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 12.03%
Debt Cost 7.62%
Equity Weight 87.97%
Equity Cost 7.62%
WACC 7.62%
Leverage 13.68%

11. Quality Control: Anika Therapeutics, Inc. passed 3 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
iCAD

A-Score: 4.8/10

Value: 7.1

Growth: 3.1

Quality: 4.7

Yield: 0.0

Momentum: 10.0

Volatility: 4.0

1-Year Total Return ->

View Full Report
Stock-Card
TriSalus Life Sciences

A-Score: 4.7/10

Value: 8.2

Growth: 4.2

Quality: 6.1

Yield: 0.0

Momentum: 7.5

Volatility: 2.3

1-Year Total Return ->

View Full Report
Stock-Card
OrthoPediatrics

A-Score: 4.0/10

Value: 8.6

Growth: 4.1

Quality: 5.5

Yield: 0.0

Momentum: 2.0

Volatility: 4.0

1-Year Total Return ->

View Full Report
Stock-Card
Bioventus

A-Score: 3.1/10

Value: 5.2

Growth: 3.3

Quality: 6.6

Yield: 0.0

Momentum: 1.0

Volatility: 2.3

1-Year Total Return ->

View Full Report
Stock-Card
Iridex

A-Score: 2.7/10

Value: 8.5

Growth: 1.8

Quality: 3.8

Yield: 0.0

Momentum: 0.5

Volatility: 1.3

1-Year Total Return ->

View Full Report
Stock-Card
Anika Therapeutics

A-Score: 2.6/10

Value: 7.0

Growth: 1.2

Quality: 3.4

Yield: 0.0

Momentum: 0.5

Volatility: 3.7

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

16.0$

Current Price

16$

Potential

-0.00%

Expected Cash-Flows